IMMUNOGENICITY AND PROTECTIVE EFFICACY OF A PROTOTYPE CAMPYLOBACTER KILLED WHOLE-CELL VACCINE IN MICE

被引:48
作者
BAQAR, S
APPLEBEE, LA
BOURGEOIS, AL
机构
关键词
D O I
10.1128/IAI.63.9.3731-3735.1995
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The immunogenicity and efficacy of an experimental inactivated Campylobacter jejuni whole-cell (CWC) vaccine were evaluated in mice. Mice were orally immunized in a three-dose primary series (48-h intervals) at doses of 10(5), 10(7), or 10(9) CWC vaccine particles alone or in combination with 25 mu g of a mucosal adjuvant, the heat-labile enterotoxin of Escherichia coli (LT). The comparative immunogenicities of both formulations were assessed on the basis of the generation of antigen-specific antibodies in serum and intestinal secretions, and efficacy was determined by measuring the degrees of protection afforded against intestinal colonization and systemic dissemination of challenge organisms. Campylobacter-specific intestinal immunoglobulin (Ig) A responses were dependent on the use of LT, whereas IgA and IgG responses in serum were not. Colonization resistance was induced over a broad range of vaccine doses when LT was included. However, only the highest dose of CWC alone gave comparable levels of protection. Both formulations provided equivalent protection against systemic spread of challenge organisms. These results indicate that both whole-cell vaccine formulations deserve further evaluation as candidate vaccines and also highlight the potential value of mucosal adjuvants, like LT, in enteric vaccine development.
引用
收藏
页码:3731 / 3735
页数:5
相关论文
共 23 条
  • [1] SAFETY AND IMMUNOGENICITY OF A PROTOTYPE ORAL WHOLE-CELL KILLED CAMPYLOBACTER VACCINE ADMINISTERED WITH A MUCOSAL ADJUVANT IN NONHUMAN-PRIMATES
    BAQAR, S
    BOURGEOIS, AL
    SCHULTHEISS, PJ
    WALKER, RI
    ROLLINS, DM
    HABERBERGER, RL
    PAVLOVSKIS, OR
    [J]. VACCINE, 1995, 13 (01) : 22 - 28
  • [2] MODULATION OF MUCOSAL IMMUNITY AGAINST CAMPYLOBACTER-JEJUNI BY ORALLY-ADMINISTERED CYTOKINES
    BAQAR, S
    PACHECO, ND
    ROLLWAGEN, FM
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (12) : 2688 - 2692
  • [3] EXPERIMENTAL CAMPYLOBACTER-JEJUNI INFECTION IN HUMANS
    BLACK, RE
    LEVINE, MM
    CLEMENTS, ML
    HUGHES, TP
    BLASER, MJ
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1988, 157 (03) : 472 - 479
  • [4] SEROLOGIC STUDY OF 2 CLUSTERS OF INFECTION DUE TO CAMPYLOBACTER-JEJUNI
    BLASER, MJ
    DUNCAN, DJ
    OSTERHOLM, MT
    ISTRE, GR
    WANG, WL
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1983, 147 (05) : 820 - 823
  • [5] CAMPYLOBACTER-JEJUNI-SPECIFIC SERUM ANTIBODIES ARE ELEVATED IN HEALTHY BANGLADESHI CHILDREN
    BLASER, MJ
    BLACK, RE
    DUNCAN, DJ
    AMER, J
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1985, 21 (02) : 164 - 167
  • [6] INFLUENCE OF STRAIN VIABILITY AND ANTIGEN DOSE ON THE USE OF ATTENUATED MUTANTS OF SALMONELLA AS VACCINE CARRIERS
    CARDENAS, L
    DASGUPTA, U
    CLEMENTS, JD
    [J]. VACCINE, 1994, 12 (09) : 833 - 840
  • [7] DISSOCIATION OF ESCHERICHIA-COLI HEAT-LABILE ENTEROTOXIN ADJUVANTICITY FROM ADP-RIBOSYLTRANSFERASE ACTIVITY
    DICKINSON, BL
    CLEMENTS, JD
    [J]. INFECTION AND IMMUNITY, 1995, 63 (05) : 1617 - 1623
  • [8] HOLMGREN J, 1990, SCAND J INFECT DIS, P47
  • [9] Jian-Xin G, 1987, Adv Exp Med Biol, V216B, P1863
  • [10] PERSISTENT CAMPYLOBACTER-JEJUNI INFECTION IN AN IMMUNOCOMPROMISED PATIENT
    JOHNSON, RJ
    NOLAN, C
    WANG, SP
    SHELTON, WR
    BLASER, MJ
    [J]. ANNALS OF INTERNAL MEDICINE, 1984, 100 (06) : 832 - 834